The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...

Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...

These real-world results support the effectiveness of maternal RSV vaccination and could influence policy decisions in other ...

This Abrysvo or Arexvy market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the ...